Archive for the ‘Latest Research’ Category

Nightstar Therapeutics has announced the initiation of the company’s STAR Phase 3 registrational trial to study the safety and efficacy

Nightstar Therapeutics held it’s Initial Public Offering on Thursday September 28th, raising $75 Million which will be used to advance

4D Molecular Therapeutics Enrolling Patients in Natural History Study in Lead Clinical Program to Develop Gene Therapy Treatment for Choroideremia 

4DMT is accepting inquires from interested choroideremia (CHM) patients for their upcoming Natural History Study.  In partnership with the Choroideremia

In a letter published by the New England Journal of Medicine today, Dr. Robert Maclaren released positive long-term results from

        4D Molecular Therapeutics and the Choroideremia Research Foundation Partner to Develop Gene Therapy Treatment for Choroideremia

At Tübingen Department of Ophthalmology in Germany, the first gene therapy trial for Choroideremia patients began on January 13th. This

An announcement today by Spark Therapeutics brings the world one step closer toward a commercially available gene therapy treatment.  This

The Bascom Palmer Eye Institute at the University of Miami has announced the opening of a clinical trial using gene

The University of Alberta, in coordination with NightstaRx, have initiated a clinical trial for patients with Choroideremia using NightstaRx’s gene